Sarepta Therapeutics, Inc. 10-Q

Item 2. Unregistered Sales of Equit y Securities and Use of Proceeds. The following is a summary of our repurchases of our common stock during the three months ended September 30, 2021: Period Total number of shares purchased (1) Weighted average price paid per share Total number of shares purchased as part of publicly announced plans or programs Approximate dollar value of shares that may yet be purchased under plans or programs July 1 – 31 — — — — August 1 – 31 — — — — September 1 – 30 1,623 $78.29 — — Total: 1,623 $78.29 — — (1) All of the 1,623 shares purchased during the three-month period ended September 30, 2021 were withheld from employees in connection with the settlement of income tax and related benefit withholding obligations arising from vesting in restricted stock grants. These shares were not part of a publicly announced program to repurchase common stock. Item 3. Defaults Upo n Senior Securities. None. Item 4. Mine Safe ty Disclosures. None.